Syrigos Nikolaos, Kollias Anastasios, Grapsa Dimitra, Fyta Eleni, Kyriakoulis Konstantinos G, Vathiotis Ioannis, Kotteas Elias, Syrigou Ekaterini
Third Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, 11527 Athens, Greece.
Department of Allergy, Sotiria Hospital, 11527 Athens, Greece.
Vaccines (Basel). 2022 May 10;10(5):745. doi: 10.3390/vaccines10050745.
This brief report examined the frequency and characteristics of a significant blood-pressure (BP) increase after Pfizer-BioNTech BNT162b2 vaccination among healthcare workers who were advised to measure their BP at home. A total of 797 participants (mean age 48.1 ± 10.8 years, 63% women, 39% smokers) were included in the analysis. Seven participants reported an increase in their BP (three in the range of grade 2 and four in the range of grade 3 hypertension). Only one participant had a history of treated hypertension. The BP increase was observed at the end of the first week after the first dose, lasted for 3 to 4 days, and recurred promptly after the second dose. Only one case required hospitalization, mainly due to a history of cardiovascular disease (follow-up). Individuals experiencing a BP increase compared with those not reporting issues with their BP had a higher mean age and similar distribution of sex and non-smoking status. In conclusion, a significant BP increase after Pfizer-BioNTech vaccination seems to be rare and of a benign and transient nature. Monitoring the BP before and after vaccination might be advisable only for selected individuals with a high cardiovascular risk.
本简要报告调查了建议在家自行测量血压的医护人员接种辉瑞-BioNTech BNT162b2疫苗后血压显著升高的频率及特征。分析共纳入797名参与者（平均年龄48.1±10.8岁，63%为女性，39%为吸烟者）。7名参与者报告血压升高（3名处于2级范围，4名处于3级高血压范围）。只有1名参与者有高血压治疗史。血压升高在首剂接种后第一周结束时出现，持续3至4天，并在第二剂接种后迅速复发。仅1例需要住院，主要是由于心血管疾病史（随访）。与未报告血压问题的个体相比，经历血压升高的个体平均年龄更高，性别和非吸烟状态分布相似。总之，辉瑞-BioNTech疫苗接种后血压显著升高似乎很少见，且具有良性和短暂性。仅对选定的心血管风险较高的个体，建议在接种前后监测血压。
